CERO Therapeutics Faces Market Dip Despite FDA Fast Track Designation

CERO Therapeutics shares are trading lower despite receiving FDA Fast Track Designation for its lead compound CER-1236 in Acute Myeloid Leukemia, as investors may have been expecting more immediate results or further clarifications on risk factors.